Table 2

Baseline, end point and change (improvement) values of individual variables and composite measures in the infliximab group of the IMPACT 2 study

BaselineWeek 54Improvement; significance of change
Pain5.5±2.12.9±2.52.5±2.8***
PtGA5.2±2.13.0±2.52.2±2.3***
EGA5.3±1.81.7±2.03.6±2.3***
SJC286.3±4.32.2±3.34.1±4.5***
TJC288.6±5.93.9±5.44.7±5.3***
SJC6611.3±6.64.2±6.47.2±8.3***
TJC6820.2±13.210.1±12.910.2±11.1***
DAS28CRP4.7±0.873.2±1.31.5±1.2***
SDAI26.8±9.611.7±11.215.1±11.3***
CDAI25.4±9.610.7±10.514.7±10.5***
DAREA43.3±17.020.4±20.122.9±19.0***
CRP (mg/dl)1.5±1.50.9±1.00.6±1.6***
SF36 pf50.3±25.568.7±27.6−18.4±24.2***
x-Ray (van der Heijde–Sharp)20.7±30.919.5±29.41.1±3.9**
  • Indicated are mean±SD; significance of the difference between baseline and end point.

  • ** p<0.01,

  • *** p<0.001.

  • CDAI, clinical disease activity index; CRP, C reactive protein; DAREA, ‘Disease Activity index for REactive Arthritis’; DAS28, Disease Activity Score using 28 joint counts; EGA, evaluator global assessment VAS (cm); IMPACT 2, Infliximab Multinational Psoriatic Arthritis Controlled Trial; pain, patient pain VAS (cm); PtGA, patient global assessment VAS (cm); SDAI, simplified disease activity index; SF36 pf, physical function domain of the SF-36 assessment; SJC, swollen joint count; TJC, tender joint count; VAS, visual analogue scale.